Indication
Malignant Germ Cell Tumor
12 clinical trials
15 products
2 drugs
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening ProtocolStatus: Recruiting, Estimated PCD: 2027-09-30
Product
EnsartinibProduct
ErdafitinibProduct
LarotrectinibProduct
OlaparibProduct
PalbociclibProduct
SamotolisibProduct
SelpercatinibProduct
SelumetinibProduct
TazemetostatProduct
TipifarnibProduct
UlixertinibProduct
VemurafenibClinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 MutationsStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Drug
IvosidenibClinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle GenesStatus: Active (not recruiting), Estimated PCD: 2023-03-31
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic AlterationsStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK FusionsStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway MutationsStatus: Active (not recruiting), Estimated PCD: 2022-03-31
Clinical trial
Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare TumorsStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Product
PembrolizumabClinical trial
A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing SarcomaStatus: Recruiting, Estimated PCD: 2025-12-31
Product
TalazoparibProduct
TMZClinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF ComplexStatus: Active (not recruiting), Estimated PCD: 2022-03-31
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic AlterationsStatus: Active (not recruiting), Estimated PCD: 2024-03-31
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene AlterationsStatus: Active (not recruiting), Estimated PCD: 2027-09-30
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-09-30